0.00
price down icon100.00%   -15.96
 
loading
전일 마감가:
$15.96
열려 있는:
$0
하루 거래량:
0
Relative Volume:
0.00
시가총액:
$22.12M
수익:
$20.97M
순이익/손실:
$-118.51M
주가수익비율:
0.00
EPS:
-2.19
순현금흐름:
$-94.45M
1주 성능:
-100.00%
1개월 성능:
-100.00%
6개월 성능:
-100.00%
1년 성능:
-100.00%
1일 변동 폭
Value
$0.00
$0.00
1주일 범위
Value
$0.00
$0.00
52주 변동 폭
Value
$0.00
$19.08

Cara Therapeutics Inc Stock (CARA) Company Profile

Name
명칭
Cara Therapeutics Inc
Name
전화
203-406-3700
Name
주소
400 ATLANTIC STREET, SUITE 500, STAMFORD, CT
Name
직원
55
Name
트위터
Name
다음 수익 날짜
2024-11-11
Name
최신 SEC 제출 서류
Name
CARA's Discussions on Twitter

CARA을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Biotechnology icon
CARA
Cara Therapeutics Inc
0.00 22.12M 20.97M -118.51M -94.45M -2.19
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
375.63 98.88B 11.42B 3.64B 3.50B 13.99
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
559.80 58.84B 14.21B 4.46B 3.56B 39.68
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
435.10 56.12B 2.46B -319.09M -52.09M -2.47
Biotechnology icon
ARGX
Argen X Se Adr
672.35 41.20B 3.05B 1.28B -614.78M 19.58
Biotechnology icon
ONC
Beone Medicines Ltd Adr
298.29 35.49B 3.81B -644.79M -669.77M -6.24

Cara Therapeutics Inc Stock (CARA) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-14 개시 Raymond James Outperform
2025-07-11 개시 Cantor Fitzgerald Overweight
2025-06-12 개시 Piper Sandler Overweight
2025-05-21 개시 Oppenheimer Outperform
2025-05-15 개시 BTIG Research Buy
2024-06-13 다운그레이드 Canaccord Genuity Buy → Hold
2024-06-13 다운그레이드 H.C. Wainwright Buy → Neutral
2024-06-13 다운그레이드 Needham Buy → Hold
2024-06-13 다운그레이드 Stifel Buy → Hold
2023-03-08 다운그레이드 BofA Securities Neutral → Underperform
2022-03-08 업그레이드 JP Morgan Neutral → Overweight
2021-11-01 재개 Canaccord Genuity Buy
2021-08-03 개시 JP Morgan Neutral
2020-04-21 재확인 H.C. Wainwright Buy
2019-08-12 재확인 H.C. Wainwright Buy
2019-05-29 재확인 Laidlaw Buy
2019-02-06 재개 Jefferies Buy
2019-01-15 개시 BofA/Merrill Neutral
2018-09-21 개시 Cantor Fitzgerald Overweight
2018-09-13 개시 Jefferies Buy
2018-08-08 재확인 Stifel Buy
2018-06-28 재확인 H.C. Wainwright Buy
2018-03-12 재개 H.C. Wainwright Buy
2018-02-12 업그레이드 Janney Neutral → Buy
2018-01-19 개시 Seaport Global Securities Buy
2017-06-30 다운그레이드 Janney Buy → Neutral
2017-06-30 재확인 Laidlaw Buy
2017-06-30 재확인 Stifel Buy
2017-03-28 재확인 H.C. Wainwright Buy
2017-03-28 재확인 Laidlaw Buy
2017-03-10 재확인 Laidlaw Buy
2016-10-13 개시 H.C. Wainwright Buy
2016-08-08 재확인 Needham Buy
모두보기

Cara Therapeutics Inc 주식(CARA)의 최신 뉴스

pulisher
Jul 29, 2025

Cara Therapeutics Inc to Host Earnings Call - ACCESS Newswire

Jul 29, 2025
pulisher
Jul 18, 2025

This ‘Strong Buy’ Stock Could Be the Next Big Biotech Breakout - Yahoo Finance

Jul 18, 2025
pulisher
Jul 18, 2025

This ‘Strong Buy’ Stock Could Be The Next Big Biotech Breakout - Barchart.com

Jul 18, 2025
pulisher
Jul 16, 2025

Tvardi Therapeutics (NASDAQ:TVRD) Coverage Initiated at Raymond James Financial - Defense World

Jul 16, 2025
pulisher
Jul 15, 2025

Tvardi Therapeutics to Participate in the BTIG Virtual Biotechnology Conference - Business Wire

Jul 15, 2025
pulisher
Jul 15, 2025

Tvardi Therapeutics director Shaheen Wirk resigns from board - Investing.com Australia

Jul 15, 2025
pulisher
Jul 14, 2025

Tvardi Therapeutics director Shaheen Wirk resigns from board By Investing.com - Investing.com Nigeria

Jul 14, 2025
pulisher
Jul 14, 2025

Raymond James Initiates Tvardi Therapeutics at Outperform - MarketScreener

Jul 14, 2025
pulisher
Jul 14, 2025

Raymond James initiates coverage on Tvardi Therapeutics stock with Outperform rating - Investing.com Nigeria

Jul 14, 2025
pulisher
Jul 14, 2025

Equities Analysts Offer Predictions for TVRD FY2025 Earnings - Defense World

Jul 14, 2025
pulisher
Jul 13, 2025

Cantor Fitzgerald Initiates Coverage on Tvardi Therapeutics (NASDAQ:TVRD) - Defense World

Jul 13, 2025
pulisher
Jul 12, 2025

Tvardi Therapeutics: A Catalyst-Driven Biotech Play with 130% Upside Potential - AInvest

Jul 12, 2025
pulisher
Jul 11, 2025

Cantor Fitzgerald initiates coverage on Tvardi Therapeutics stock with Overweight rating - Investing.com

Jul 11, 2025
pulisher
Jul 11, 2025

Cantor Fitzgerald Initiates Tvardi Therapeutics at Overweight With $52 Price Target - MarketScreener

Jul 11, 2025
pulisher
Jun 30, 2025

Tvardi Therapeutics, Inc.(NasdaqCM: TVRD) added to Russell Microcap Growth Index - MarketScreener

Jun 30, 2025
pulisher
Jun 13, 2025

Cara Therapeutics (NASDAQ:TVRD) Now Covered by Analysts at Piper Sandler - Defense World

Jun 13, 2025
pulisher
Jun 12, 2025

Recently Listed Tvardi Therapeutics' Lead Drug 'Positioned To Drive Broad Improvement', Analyst Sees Over 150% Stock Upside - Benzinga

Jun 12, 2025
pulisher
Jun 12, 2025

Cara Therapeutics (NASDAQ:TVRD) Coverage Initiated by Analysts at Piper Sandler - MarketBeat

Jun 12, 2025
pulisher
Jun 12, 2025

Piper Sandler Initiates Coverage on Tvardi Therapeutics With Overweight Rating - MarketScreener

Jun 12, 2025
pulisher
Jun 12, 2025

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating - Investing.com Australia

Jun 12, 2025
pulisher
Jun 12, 2025

Piper Sandler initiates Tvardi Therapeutics stock with overweight rating By Investing.com - Investing.com Canada

Jun 12, 2025
pulisher
Jun 11, 2025

How To Trade (CARA) - news.stocktradersdaily.com

Jun 11, 2025
pulisher
Jun 09, 2025

Tvardi Therapeutics Updates Corporate Presentation on Therapies - TipRanks

Jun 09, 2025
pulisher
May 29, 2025

Cara Therapeutics, Inc. (NASDAQ:CARA) Given Average Rating of “Hold” by Brokerages - Defense World

May 29, 2025
pulisher
May 29, 2025

Oppenheimer Begins Coverage on Cara Therapeutics (NASDAQ:TVRD) - MarketBeat

May 29, 2025
pulisher
May 28, 2025

BTIG maintains $55 target on Tvardi stock, reiterates buy By Investing.com - Investing.com South Africa

May 28, 2025
pulisher
May 28, 2025

BTIG maintains $55 target on Tvardi stock, reiterates buy - Investing.com

May 28, 2025
pulisher
May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of Tti-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Tvardi Therapeutics Announces Completion of Enrollment in Phase 2 Clinical Trial of TTI-101 in Idiopathic Pulmonary Fibrosis - marketscreener.com

May 27, 2025
pulisher
May 27, 2025

Tvardi Completes Enrollment for Phase 2 IPF Trial - TipRanks

May 27, 2025
pulisher
May 26, 2025

Cara Therapeutics (NASDAQ:TVRD) Raised to “Hold” at Wall Street Zen - Defense World

May 26, 2025
pulisher
May 21, 2025

TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism By Investing.com - Investing.com South Africa

May 21, 2025
pulisher
May 21, 2025

TVRD Stock Hits 52-Week High at $29.22 Amid Market Optimism - Investing.com

May 21, 2025
pulisher
May 21, 2025

Oppenheimer sets $65 target on Tvardi stock with Outperform rating - Investing.com

May 21, 2025
pulisher
May 21, 2025

Oppenheimer sets $65 target on Tvardi stock with Outperform rating By Investing.com - Investing.com India

May 21, 2025
pulisher
May 16, 2025

Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com - Defense World

May 16, 2025
pulisher
May 15, 2025

BTIG sets $55 target on Tvardi Therapeutics stock with Buy rating - Investing.com UK

May 15, 2025
pulisher
May 14, 2025

Cara Therapeutics Stock Jumps 10% After Announcing 1-for-3 Reverse Stock Split: Retail Sentiment Soars - MSN

May 14, 2025
pulisher
May 14, 2025

Tvardi Therapeutics Reports Q1 2025 Financial Results - TipRanks

May 14, 2025
pulisher
May 14, 2025

Tvardi maps out path to Phase II data after Cara merger - The Pharma Letter

May 14, 2025
pulisher
May 13, 2025

Tvardi Therapeutics Announces First Quarter 2025 Results and Provides Business Update - Business Wire

May 13, 2025
pulisher
May 08, 2025

Where are the Opportunities in (CARA) - news.stocktradersdaily.com

May 08, 2025
pulisher
May 06, 2025

Tvardi Therapeutics Announces Presentation at the American Thoracic Society 2025 Annual Conference - Business Wire

May 06, 2025

Cara Therapeutics Inc (CARA) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading
$78.20
price up icon 0.71%
$37.01
price down icon 0.30%
$109.30
price down icon 1.76%
$28.07
price down icon 1.58%
$111.35
price up icon 0.04%
biotechnology ONC
$298.29
price down icon 0.08%
자본화:     |  볼륨(24시간):